GeneXpert MTB/RIF 版本 G4 在规划环境中用于鉴定利福平耐药结核。
GeneXpert MTB/RIF version G4 for identification of rifampin-resistant tuberculosis in a programmatic setting.
机构信息
City Health Directorate, City of Cape Town, South Africa.
出版信息
J Clin Microbiol. 2014 Feb;52(2):635-7. doi: 10.1128/JCM.02517-13. Epub 2013 Nov 27.
Abstract
A recent Cochrane review estimated GeneXpert MTB/RIF specificity for rifampin resistance as 98% (95% confidence interval [CI], 97 to 99), based on results from earlier test versions. The measured positive predictive value of the new generation test from programmatic implementation in Cape Town, South Africa, was 99.5% (95% CI, 98.5 to 100), confirming excellent specificity.
摘要
最近的 Cochrane 综述估计 GeneXpert MTB/RIF 对利福平耐药的特异性为 98%（95%置信区间 [CI]，97 至 99），这是基于早期测试版本的结果。在南非开普敦进行规划实施时，新一代测试的阳性预测值为 99.5%（95%CI，98.5 至 100），证实了其极好的特异性。
Zotero 插件